ZURICH (Reuters) – Google’s ambition to defy the limits of ageing has fired up interest in the field, drawing in drug companies who are already quietly pioneering research, despite the regulatory and clinical hurdles that remain.
In September life-science company Calico, which was set up by Google last year to investigate the aging process, joined with U.S. drugmaker AbbVie in committing an initial $250 million apiece to developing cures for age-related diseases.
ZURICH (Reuters) – Google’s (GOOG.O: Quote, Profile, Research) ambition to defy the limits of ageing has fired up interest in the field, drawing in drug companies who are already quietly pioneering research, despite the regulatory and clinical hurdles that remain.
In September life-science company Calico, which was set up by Google last year to investigate the ageing process, joined with U.S. drugmaker AbbVie (ABBV.N: Quote, Profile, Research) in committing an initial $250 million (156.59 million pound) apiece to developing cures for age-related diseases.
ZURICH, Nov 3 (Reuters) – Swiss building materials group
Holcim posted a drop in quarterly sales and profits on
Monday as a recovery in India following May’s elections failed
to offset foreign exchange headwinds and weakness in Europe and
The group, which is in the process of merging with France’s
Lafarge, reported higher sales in markets such as the
United States and India, where infrastructure spending has
picked up following the election victory of Narendra Modi who
campaigned to revive stalled construction projects.
ZURICH, Oct 31 (Reuters) – Switzerland’s Lonza
revised down its forecast for full-year revenue growth on Friday
as bad weather weighed on the performance of its water treatment
This is the second time in two years that the water
business, which makes products to sanitize swimming pools,
pulled down the company’s results following a poor 2013. Lonza
acquired the business as a part of its $1.2 billion acquisition
of Arch Chemicals in 2011
ZURICH (Reuters) – Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research, Stock Buzz) reported better-than-expected results on Tuesday, as strong sales of new products and its leukemia drug Glivec helped offset full copycat competition to its former best-selling blood pressure pill Diovan.
The Basel-based firm, in the middle of a radical portfolio revamp, is counting on products launched in the past five years to help support sales as it battles a series of patent losses on top-selling drugs.
ZURICH, Oct 23 (Reuters) – Swiss dental implant maker
Straumann Holding AG raised its profit outlook on
Thursday after notching up its strongest revenue growth in 15
quarters, helped by buoyant demand in the United States, China
The premium dental implant market has show signs of a
turnaround in recent quarters, after the global economic
downturn encouraged consumers in developed countries to postpone
non-urgent dental treatment and trade down to cheaper brands.
ZURICH (Reuters) – Bleaker global growth prospects are keeping Swiss engineer ABB (ABBN.VX: Quote, Profile, Research, Stock Buzz) cautious about its prospects, despite a bigger-than-expected rise in third-quarter orders and a return to profit at its troubled power systems business.
The company, which makes products such as industrial robots and power grid transformers, said on Wednesday slowing growth in Europe, the Ebola health crisis in west Africa and political tensions across the globe all risked derailing more positive trends in the U.S. and Chinese economies.
ZURICH, Oct 22 (Reuters) – Swiss drugmaker Roche
said on Wednesday it would spend 3 billion Swiss francs ($3.2
billion) to upgrade its Basel site, a vote of confidence in its
Swiss base despite ongoing uncertainty over the country’s
The company – which traces its roots in Basel to 1896 when
Fritz Hoffman-La Roche set up the business – said it would
invest in a new research and development centre, build a new
office tower and upgrade existing infrastructure and buildings.
ZURICH (Reuters) – Actelion (ATLN.VX: Quote, Profile, Research, Stock Buzz) raised its 2014 earnings guidance on Tuesday for the third time this year, buoyed by a strong start to its new heart and lung drug and better-than-expected profit in the third quarter.
Europe’s biggest biotech company said on Tuesday it was encouraged by the uptake for Opsumit, its new treatment for pulmonary arterial hypertension (PAH), which won approval in the United States and Europe at the end of last year.
ZURICH (Reuters) – Swiss drugs firm Roche reported better than expected third-quarter sales on Thursday, boosted by a strong performance from its new breast cancer drugs.
The world’s largest maker of cancer drugs said group sales rose 2 percent to 11.78 billion Swiss francs ($12.5 billion), slightly ahead of the average forecast of 11.57 billion given by analysts in a Reuters poll.